# Valerio Therapeutics clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Valerio Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Valerio Therapeutics: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/valerio-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 14, 2024 | NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Valerio Therapeutics | Phase 1/2 | Terminated | Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06257758) |
| January 26, 2023 | NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | Valerio Therapeutics | Phase 1/2 | Completed | Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05700669) |
| July 6, 2018 | NCT03579628 | AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors | Valerio Therapeutics | Phase 1 | Completed | Advanced Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03579628) |
| September 14, 2015 | NCT02548806 | Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers | Valerio Therapeutics | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02548806) |
| January 9, 2013 | NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma | Valerio Therapeutics | Phase 1/2 | Withdrawn | Melanoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01764009) |
| August 2, 2012 | NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma | Valerio Therapeutics | Phase 3 | Completed | Carcinoma, Hepatocellular | 397 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01655693) |
| June 30, 2011 | NCT01385748 | Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis | Valerio Therapeutics | Phase 2 | Completed | Oral Mucositis | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01385748) |
| January 11, 2010 | NCT01045915 | Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma | Valerio Therapeutics | Phase 1 | Terminated | Melanoma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01045915) |
| April 9, 2009 | NCT00878800 | A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | Valerio Therapeutics | Phase 1/2 | Completed | Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00878800) |
| April 9, 2009 | NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | Valerio Therapeutics | Phase 1/2 | Completed | Acute Myeloid Leukemia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00878722) |
| April 1, 2009 | NCT00873119 | Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | Valerio Therapeutics | Phase 2 | Completed | Carcinoma of Unknown Primary | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00873119) |
| October 9, 2008 | NCT00769314 | Phase 3 Clinical Study for the Treatment of Cold Sore | Valerio Therapeutics | Phase 3 | Completed | Herpes Labialis | 1,727 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00769314) |
| October 24, 2007 | NCT00548704 | A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines | Valerio Therapeutics | Phase 2/3 | Completed | Extravasation | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00548704) |
| October 24, 2007 | NCT00548561 | Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines | Valerio Therapeutics | Phase 2/3 | Completed | Anthracycline Extravasation | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00548561) |
| February 21, 2007 | NCT00437736 | A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors | Valerio Therapeutics | Phase 1 | Completed | Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00437736) |
| February 14, 2007 | NCT00435084 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | Valerio Therapeutics | Phase 1/2 | Completed | B-cell Chronic Lymphocytic Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00435084) |
| February 7, 2007 | NCT00432107 | A Study to Assess APO866 for the Treatment of Advanced Melanoma | Valerio Therapeutics | Phase 2 | Completed | Melanoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00432107) |
| February 6, 2007 | NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | Valerio Therapeutics | Phase 2 | Completed | Cutaneous T-cell Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00431912) |
| February 5, 2007 | NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | Valerio Therapeutics | Phase 2 | Terminated | Multiple Myeloma | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00431340) |
| January 15, 2007 | NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | Valerio Therapeutics | Phase 1/2 | Completed | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00421889) |
| December 19, 2006 | NCT00413322 | Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | Valerio Therapeutics | Phase 1 | Completed | Tumor | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00413322) |
| December 19, 2006 | NCT00413075 | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | Valerio Therapeutics | Phase 1 | Completed | Solid Tumor, Lymphoma | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00413075) |
| October 20, 2006 | NCT00390780 | Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients | Valerio Therapeutics | Phase 3 | Completed | HIV Infections | 578 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00390780) |
| January 11, 2006 | NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | Valerio Therapeutics | Phase 2 | Terminated | Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00274651) |
| August 18, 2005 | NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | Valerio Therapeutics | Phase 2 | Completed | Multiple Myeloma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00131261) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 7 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Neoplasms | 3 |
| Urinary Bladder Neoplasms | 3 |
| Sarcoma | 3 |
| Melanoma | 3 |
| Multiple Myeloma | 2 |
| Adenosarcoma | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Carcinoma, Small Cell | 2 |
| Chondrosarcoma | 2 |
| Colorectal Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Fibrosarcoma | 2 |
| Head and Neck Neoplasms | 2 |
| Hemangiosarcoma | 2 |
| Kidney Neoplasms | 2 |
| Leiomyosarcoma | 2 |
| Liposarcoma | 2 |
| Lung Neoplasms | 2 |
| Mesothelioma | 2 |
| Mesothelioma, Cystic | 2 |
| Mixed Tumor, Mesodermal | 2 |
| Osteosarcoma | 2 |
| Otorhinolaryngologic Neoplasms | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Law firms in the United States](https://specstream.ai/data/businesses/law-firms/united-states)
- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
- [Surgical supply companies in the United States](https://specstream.ai/data/businesses/surgical-supply-companies/united-states)
- [Junk removal companies in the United States](https://specstream.ai/data/businesses/junk-removal-companies/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
